Kazancioglu Alp, Ozdemiral Cansu, Gur Cetinkaya Pinar, Ocak Melike, Sahiner Umit Murat, Sekerel Bulent Enis, Soyer Ozge
Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara, Turkey.
Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara, Turkey.
Ann Allergy Asthma Immunol. 2025 Jul 21. doi: 10.1016/j.anai.2025.07.014.
The long-term progression of allergic conditions in children with a history of food protein-induced allergic proctocolitis (FPIAP) remains unclear.
To assess the prevalence and clinical characteristics of allergic diseases, particularly asthma, in patients with a history of FPIAP.
In this retrospective case-control study, we included 170 patients diagnosed with having FPIAP (median age [IQR]: 7.4 [6.9-8.0] years) who developed tolerance at a median age of 12 months (IQR: 10.0-14.0). Control groups comprised patients with non-food allergy (non-FA; n = 101), outgrown IgE-mediated cow's milk allergy (IgE-CMA; n = 97), and current IgE-CMA (n = 100). The proportions of asthma and allergic rhinitis (AR) were compared among the groups.
The FPIAP group exhibited a higher risk of developing asthma and AR than the non-FA group did (asthma: adjusted odds ratio: 4.273, 95% CI: 2.173-8.403, P < .001; AR: adjusted odds ratio: 3.039, 95% CI: 1.199-7.692, P = .019). The proportions of asthma and AR in the FPIAP group (45.2% and 17.6%, respectively) were significantly higher than those in the non-FA group (12.9%, P < .001; 5.9%, P = .006) but lower than those in the current IgE-CMA group (74%, P < .001; 36%, P = .001). No significant differences were observed between the FPIAP and outgrown IgE-CMA groups. However, patients with FPIAP exhibited poorer asthma control than those in the IgE-mediated CMA groups did.
Children with a history of FPIAP are at an increased risk of developing asthma and AR, necessitating ongoing monitoring. Further research is needed to clarify the role of FPIAP in the allergic march.
有食物蛋白诱导的过敏性直肠结肠炎(FPIAP)病史的儿童过敏性疾病的长期进展尚不清楚。
评估有FPIAP病史的患者中过敏性疾病,尤其是哮喘的患病率和临床特征。
在这项回顾性病例对照研究中,我们纳入了170例被诊断为患有FPIAP的患者(中位年龄[四分位间距]:7.4[6.9 - 8.0]岁),他们在中位年龄12个月(四分位间距:10.0 - 14.0)时产生了耐受性。对照组包括非食物过敏患者(非FA;n = 101)、已自愈的IgE介导的牛奶过敏患者(IgE - CMA;n = 97)和当前IgE - CMA患者(n = 100)。比较各组中哮喘和过敏性鼻炎(AR)的比例。
FPIAP组发生哮喘和AR的风险高于非FA组(哮喘:调整后的优势比:4.273,95%置信区间:2.173 - 8.403,P <.001;AR:调整后的优势比:3.039,95%置信区间:1.199 - 7.692,P =.019)。FPIAP组中哮喘和AR的比例(分别为45.2%和17.6%)显著高于非FA组(12.9%,P <.001;5.9%,P =.006),但低于当前IgE - CMA组(74%,P <.001;36%,P =.001)。FPIAP组和已自愈的IgE - CMA组之间未观察到显著差异。然而,有FPIAP病史的患者哮喘控制情况比IgE介导的CMA组患者差。
有FPIAP病史的儿童发生哮喘和AR的风险增加,需要持续监测。需要进一步研究以阐明FPIAP在过敏性进程中的作用。